<p>Coinvestigators</p><p>Work on this study was conducted on the behalf of the ITN STAyCIS Study Group. </p><p>Investigators: S.S. Zamvil MD, PhD (Protocol Chair), E. Waubant MD, PhD (Protocol Co-</p><p>Chair), D. Pelletier MD (University of California, San Francisco, San Francisco, CA); M. Mass </p><p>MD, D. Bourdette MD, R. Egan MD (Oregon Health & Science University, Portland, OR); J. </p><p>Cohen MD, L. Stone MD (The Cleveland Clinic Foundation, Cleveland, OH); M. Kita MD, M. </p><p>Elliott MD (Virginia Mason MS Center, Seattle, WA); A. Cross MD, B.J. Parks MD </p><p>(Washington University MS Center, St. Louis, MO); A. Bar-Or MD (Montreal Neurological </p><p>Institute, Montreal, Quebec, Canada); T. Vollmer MD, D. Campagnolo MD (Barrow </p><p>Neurological Institute, Phoenix, AZ); M. Racke MD, O. Stüve MD, PhD, E. Frohman MD, PhD </p><p>(University of Texas Southwestern Medical Center, Dallas, TX); S. Schwid MD (deceased), A. </p><p>Goodman MD, B. Segal MD (University of Rochester, Rochester, NY); N. Kachuck MD, L. </p><p>Weiner MD (University of Southern California, Keck School of Medicine MS Center, Los </p><p>Angeles, CA); J. Preiningerova MD, M. Carrithers MD, PhD (Yale MS Research Center, New </p><p>Haven, CT); B. Weinstock-Guttman (Jacobs Neurological Institute, Buffalo, NY); P. Calabresi </p><p>MD, D. Kerr MD, PhD (Johns Hopkins University, Baltimore, MD); A. Miller MD, F. Lublin </p><p>MD (Mt. Sinai School of Medicine, New York, NY). ITN020AI Study Management Team: Peter </p><p>Sayre MD, PhD (Executive Director, ITN Clinical Trials Group, San Francisco, CA); Deborah </p><p>Hayes MS, Ellen Rosenberg MA, BSN, RN, Wendy Gao RN, MS (NIAID Project Managers, </p><p>Bethesda, MD); Linna Ding MD, PhD (NIAID Medical Monitor, Bethesda, MD); Steven Adah, </p><p>PhD (NIAID Senior Regulatory Officer, Bethesda MD); Masoud Mokhtarani MD, Jutta </p><p>Neuenburg MD (ITN Clinical Trial Physicians, San Francisco, CA); Carolyn Bromstead, Lynn </p><p>Olinger, Blair Mullen, Ross Jamison, Kelly Speth, Kerensa Saljooqi, Peter Phan (ITN Clinical Operations Managers, San Francisco, CA). Deborah Phippard PhD, Vicki Seyfert-Margolis PhD,</p><p>Katarzyna Bourcier PhD (ITN Trial Assay Development Analysis, Bethesda, MD); Tracia </p><p>Debnam MS, Jennifer Romaine, Stephanie Wolin, Brittany O’Dale (ITN Tolerance Research </p><p>Project Management Operations, Bethesda, MD). David Iklé PhD, Stacey Murphy MS, Heather</p><p>Kopetskie (Biostatisticians, Rho Inc., Chapel Hill, NC). </p>